Document:

Pursuant to 17 CFR 229.601(b)(10)(iv), confidential information (indicated by [***]) has been omitted from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed.

      Exhibit 10.12.5

       

      Execution Version

    

    
       

      FOURTH AMENDMENT TO

        MASTER SERVICES AGREEMENT

    

    
       

      This Fourth Amendment (the “Amendment”) to the Master Services Agreement dated December 6, 2013, as amended, by and between Aegerion Pharmaceuticals, Inc. (“Aegerion”), as assignee of AstraZeneca
        Pharmaceuticals LP, and Accredo Health Group, Inc. (“Service Provider”) (the “Agreement”) is effective as of October 19, 2017 (the “Amendment Effective Date”). Any capitalized terms used but not defined in this Amendment shall have the meanings
        ascribed to them in the Agreement.

       

      WHEREAS, the parties desire to amend certain terms of the Agreement to reflect its assignment from AstraZeneca to Aegerion.

    

    
       

      NOW, THEREFORE, in consideration of the mutual covenants contained in this Amendment and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties
        agree as follows:

    

    
       

      
        		1.	
                All references to AstraZeneca in the Agreement are hereby changed to Aegerion and Aegerion hereby assumes all of the rights and responsibilities of AstraZeneca set forth in the Agreement.

              

      

       

      
        		2.	
                Section 1.30(j) is hereby deleted in its entirety and replaced with the following:

              

      

    

    
       

      “The delivery, storage, shipment, sale, or handling of any Product.”

    

    
       

      
        		3.	
                Section 1.3(1) is hereby deleted in its entirety and replaced with the following:

              

      

    

    
       

      “Reserved”

    

    
       

      
        		4.	
                Section 2.7(a) is hereby deleted in its entirety and replaced with the following:

              

      

    

    
       

      “Aegerion will reimburse Service Provider for all reasonable out-of-pocket expenses incurred or paid by Service Provider in connection with the performance of Services by under this Agreement, but in
        each case solely to the extent such expenses have been authorized in advance in writing by an authorized representative of Aegerion or are otherwise specifically
        listed as reimbursable expenses on Attachment 2 attached hereto and incorporated herein by reference. Service Provider will furnish appropriate supporting documentation for authorized expenses to be reimbursed by Aegerion under this Agreement. All
        fees and expenses incurred by Service Provider in performing Services under this Agreement that are not specifically listed as part of fees and reimbursable expenses on Attachment 2 or otherwise expressly authorized in advance in writing by an
        authorized representative of Aegerion will be borne by Service Provider.”

    

    
       

      
        		5.	
                Section 3.1 of the Agreement - Payment - is hereby amended by replacing [***] with [***].

              

      

       

      
        		6.	
                Section 4.1 - Term - is hereby deleted and replaced in its entirety with the following:

              

      

    

    
       

      “This Agreement shall commence on the Effective Date and, unless terminated earlier in accordance with Section 5, below, shall expire on September 30, 2019 and shall automatically renew for an
        additional one year term ending September 30, 2020 unless

    

    
       

      
        1

        
          
 

      

    

    
      Execution Version

       

      either party gives written notice of non-renewal to the other at least 180 days prior to September 30, 2019.”

    

    
       

      
        		7.	
                Section 9.1(f) of the Agreement is hereby deleted and replaced with the following:

              

      

    

    
       

      “Services performed by a nurse or pharmacist under this Agreement shall be performed only through qualified, trained and competent nurses and pharmacists. Each such nurse and pharmacist shall (i)
        possess a current and valid license, certification, or legal authorization, as applicable, in his/her applicable profession in each state in which he/she performs services; and (ii) be and remain in good standing in the applicable state.”

    

    
       

      
        		8.	
                Section 9.1(z) of the Agreement – Audit Rights – is hereby deleted and replaced with the following:

              

      

    

    
       

      “Service Provider guarantees an acknowledgement response time within three (3) business days for all month end, quarter end, and other financial inquiries received from Aegerion. In addition, Service
        Provider agrees to and will comply with the obligations set forth in Attachment – Audit.”

    

    
       

      
        		9.	
                The Agreement is hereby amended by (a) inserting new Exhibit B thereto as the same is attached hereto and incorporated herein by reference, and (b) deleting Section 9.1(aa) of the Agreement - Adverse Event Reporting - in its entirety
                  and replacing it with the following:

              

      

    

    
       

      “See Exhibit B attached hereto and incorporated herein by reference”.

    

    
       

      
        		10.	
                Section 14.1 of the Agreement - Notice - is hereby amended by deleting in its entirety the Notice addresses for AstraZeneca and replacing them with the following:

              

      

    

    

       

    	 	
            “For:

          	
            Aegerion Pharmaceuticals, Inc.

          
	 	
            Address:   

            

          	
                          One Main Street, Suite 800

          
	 	 	
            Cambridge, MA 02142

          
	 	 	
            Attn: President

          
	 	 	 
	 	
            With a copy to:

          	 
	 	
            Address:

          	
            Aegerion Pharmaceuticals, Inc.

          
	 	 	
            One Main Street, Suite 800

          
	 	 	
            Cambridge, MA 02142

          
	 	 	
            Attn: Vice President, Legal”

          

    
       

      
        		11.	
                Section 13.1 - Business Conduct and Ethics - is hereby replaced in its entirety with the following:

              

      

    

    
       

      “Aegerion takes seriously its compliance and ethics responsibilities and seeks to do business only with third parties who share high standards of ethical behavior. To that end, Aegerion has adopted
        the Business Partner Guiding Principles a copy of which is attached hereto and incorporated herein as Attachment 1. Service Provider abides by its parent company’s Code of Conduct, available at
        https://express-scripts. com/aboutus/codeconduct/ExpressScriptsCodeOfConduct.pdf.

    

    
       

      
        2

        
          
 

      

    

    
      Execution Version

       

      
        		12.	
                Section 2.7 of the Agreement is hereby deleted in its entirety and replaced with the following:

              

      

    

    
       

      “2.7 Reimbursable Expenses

    

    
       

      2.7(a) Aegerion will reimburse Service Provider for all reasonable and necessary business and travel expenses and pass-through costs actually incurred by Service Provider in the course of performing
        Services at cost without mark-up (“Reimbursable Expenses”).

       

      2.7(b) Service Provider shall obtain Aegerion’s written approval prior to incurring any travel expenses that will be invoiced to Aegerion under this Agreement as Reimbursable Expenses.

       

      2.7(c) Service Provider agrees to invoice Aegerion for Reimbursable Expenses, which invoice will be accompanied by any supporting documentation (e.g. receipts) required by Aegerion.

       

      2.7(d) Aegerion will have no obligation to reimburse Service Provider for any Reimbursable Expenses unless and until all documentation required by this Agreement and Aegerion is received from Service
        Provider.”

    

    
       

      
        		13.	
                Section 15.5 of the Agreement - Governing Law - is hereby amended by replacing “State of New Jersey” with “State of New York”.

              

      

       

      
        		14.	
                The Attachment to the Agreement entitled “ATTACHMENT – PERSONAL DATA” is amended and restated in its entirety as set forth in the new “ATTACHMENT – PERSONAL DATA” attached hereto and incorporated herein by reference.

              

      

       

      
        		15.	
                The Agreement is hereby amended by inserting the following text as Section 16 of the Agreement:

              

      

    

    
       

      
        		“16.	
                Compliance

              

      

       

      
        		16.1	
                General. The requirements of this Section 16 shall apply to all employees, agents, contractors and subcontractors of Service Provider that provide goods or services to Aegerion pursuant to this Agreement (collectively,
                  “Personnel”). Service Provider shall ensure that all Personnel abide by the requirements set forth in this Section 16. To the extent that Service Provider reasonably expects that any Personnel will provide goods or services to Aegerion in
                  excess of [***] during a contract year, then Service Provider shall specifically furnish the names of such Personnel to Aegerion (“Listed Personnel”) within [***] following the execution of the fourth amendment to this Agreement. Service
                  Provider shall notify Aegerion with any changes to the Listed Personnel within [***] of Service Provider’s first knowledge thereof.

              

      

       

      
        		16.2	
                Training; Aegerion Compliance Policies and Procedures.

              

      

    

    
       

      
        		16.2(a)	
                Within [***] of the execution of the fourth amendment to this Agreement, or a longer period if approved by Aegerion in writing, Service Provider shall ensure that all Listed Personnel have completed all compliance training required by
                  Aegerion, which shall be limited to

              

      

    

     

    
      3

      
        
 

    

    
      
        Execution Version

         

      

      compliance training that Aegerion has agreed to ensure Listed Personnel complete. If requested by Aegerion for Listed Personnel, the training and certification will be provided by Aegerion through
        Aegerion’s corporate learning management system. In addition, Service Provider shall ensure that all Listed Personnel shall timely complete any compliance training required by Aegerion during the term of this Agreement.

    

    
       

      
        		16.2(b)	
                Upon request from Aegerion, Service Provider shall certify to the completion of all required training by all Listed Personnel.

              

      

       

      
        		16.2(c)	
                Service Provider shall ensure that its Listed Personnel promptly review any updated Aegerion compliance policies and procedures that are provided to Service Provider by Aegerion.

              

      

       

      
        		16.2(d)	
                Upon request from Aegerion, Service Provider shall certify in writing, in the manner and form reasonably determined by Aegerion, that Listed Personnel received, read, understood and will abide by all required Aegerion compliance
                  policies and procedures, including the Aegerion Code of Conduct.

              

      

    

    
       

      
        		16.3	
                Violations. Service Provider shall ensure Listed Personnel promptly report to the Aegerion Compliance Department any suspected or actual violations of criminal, civil, or administrative law or Aegerion compliance policies
                  observed during the performance of this Agreement. Any such report can be made, on an attributed or anonymous basis, by writing to the Chief Compliance Officer c/o Aegerion Pharmaceuticals, Inc., One Main St., Ste. 800, Cambridge, MA
                  02142, calling 855-233-8089 or visiting https://novelioncompliance.tnwreports.com. Service Provider agrees to appropriately
                  publicize to Personnel the ability to make such reports (e.g., via periodic e-mails to Personnel, or by posting the information in prominent common areas), and shall emphasize a nonretribution, nonretaliation policy regarding such
                  reports.

              

      

       

      
        		16.4	
                Ineligible Persons. Service Provider represents and warrants that, as of the effective date of the fourth amendment to this Agreement, it is not, and no Personnel are, an “Ineligible Person,” defined as any individual or entity
                  who: (i) is currently excluded from participation in Federal health care programs or (ii) has been convicted of a criminal offense that falls within the scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded. Service Provider
                  shall screen all prospective Personnel against the HHS/OIG List of Excluded Individuals/Entities (LEIE) (available through the Internet at http://www.oig.hhs.gov) (“Exclusion List”)). Service Provider shall screen all Personnel against
                  the Exclusion List in accordance with its policies (which shall be no less frequently than quarterly) and shall promptly notify Aegerion if Service Provider or any Listed Personnel become an Ineligible Person. Notwithstanding any other
                  provision of this Agreement, Aegerion may terminate this Agreement immediately upon Service Provider becoming an Ineligible Person. If Service Provider has actual notice that Listed Personnel becomes an Ineligible Person, then Service
                  Provider agrees to promptly notify Aegerion and to immediately remove such Personnel from any further responsibilities for, or involvement with, providing services to Aegerion.

              

      

    

    
       

      
        4

        
          
 

      

    

    
      Execution Version

       

      
        	
                 

                 

                 

              	16.5	
                Records; Inspections; Requests for Information. Service Provider agrees to keep business records, including documents relating to (a) goods and services provided to Manufacturer under the Agreement and (b) compliance with the
                  requirements of the fourth amendment to this Agreement, until six (6) years from the expiration or termination of the Agreement. Upon the expiration of such six (6) years, Service Provider will transfer such documents and records to
                  Manufacturer if requested by Manufacturer at Manufacturer’s expense. Service Provider agrees to permit Manufacturer, or any third party person(s) designated by Manufacturer (including, but not limited to, Manufacturer’s CIA Independent
                  Review Organization, Manufacturer’s Consent Decree Independent Auditor and Manufacturer Quality Assurance) to inspect such records according to the terms of ATTACHMENT – AUDIT to the Agreement. When Manufacturer is required to obtain
                  information from Service Provider outside the annual audit, Service Provider agrees to respond promptly to any such requests for information from Manufacturer or any third party person(s) designated by Manufacturer (including, but not
                  limited to, Manufacturer’s CIA Independent Review Organization, Manufacturer’s Consent Decree Independent Auditor and Manufacturer Quality Assurance). Such requests outside of the annual audit, unless they are for cause due to Service
                  Provider’s fault, will be subject to a fee of $250 per hour.”

              

      

    

    
       

      
        		16.	
                Schedule 16 to this Amendment is hereby attached to and incorporated into the Agreement as Schedule 16.

              

      

       

      
        		17.	
                Paragraph 1 of “ATTACHMENT – AUDIT” to the Agreement is hereby deleted in its entirety and replaced with the following:

              

      

    

    
       

      “1. maintain during the term of this Agreement and for the period of six years thereafter sufficient documentation necessary to demonstrate compliance with the requirements of this Agreement and
        provide for review to Aegerion during an on-site audit, policies, procedures, and records used or produced by Service Provider in relation to its performance of its obligations under this Agreement, and provide upon request to Aegerion, the FDA, or
        a third party acting on behalf of Aegerion or FDA documentation that all processes and procedures are in place and are being followed for any applicable Risk Evaluation Mitigation Strategy where required, which may include joint review during a
        WebEx session, for example to validate that changes have been made to a Product-specific SOP prior to implementation. The parties agree not to take screen shots of such WebEx sessions;”

    

    
       

      
        		18.	
                Paragraph 2 of “ATTACHMENT – AUDIT” to the Agreement is hereby deleted in its entirety and replaced with the following:

              

      

    

    
       

      “2. allow Aegerion (or its designee), upon (i) [***] written notice or (ii) for initial audits of new specialty pharmacies, [***] written notice, accompanied by a detailed scope, during the term of
        this Agreement and for the period of [***] thereafter, to audit Service Provider’s and Service Provider’s agents’ and subcontractors’ documents, books, records, procedures, systems and facilities and conduct interviews with people under their
        control. Aegerion may conduct such audits (i) without cause not more frequently than once per calendar year, (ii) for cause (including, without limitation, audits based on Aegerion’s reasonable belief that a violation has occurred, audits related
        to quality control standards, and audits to confirm resolution of adverse

    

     

    
      5

      
        
 

    

    
      Execution Version

       

    

    findings from a prior audit) at Aegerion’s reasonable discretion, and (iii) to assess compliance with requirements related to any applicable Risk Evaluation Mitigation
      Strategy (REMS) at Aegerion’s reasonable discretion. If a third party is used to conduct any audit, such third-party with sign a confidentiality agreement with the audited party. Each such audit shall be subject to, and wholly covered by, the mutual
      confidentiality protections of this Agreement;”

    
       

      
        		19.	
                Paragraph 7 of “ATTACHMENT – AUDIT” is hereby deleted in its entirety and replaced with the following:

              

      

    

    
       

      “notify Aegerion promptly (but in no event later than within [***]) after Service Provider’s receipt of notice of a proposed inspection by a government or regulatory authority that relates directly to
        this Agreement or the transactions contemplated by it and allow Aegerion on site for such on-site inspection that relates directly to any Product; and”

    

    
       

      
        		20.	
                This Amendment may be executed in two or more counterparts, each of which shall be deemed an original and all of which shall together be deemed to constitute one agreement. The parties agree that execution of this Amendment by
                  exchanging facsimile or PDF signatures shall have the same legal force and effect as the exchange of original signatures.

              

      

       

      
        		21.	
                This Amendment, together with the Agreement, constitutes the entire agreement between the parties with respect to the subject matter of the Agreement. The Agreement together with this Amendment supersedes all prior agreements, whether
                  written or oral, with respect to the subject matter of the Agreement. The parties hereby agree that subject to the modifications specifically stated in this Amendment, all terms and conditions of the Agreement shall remain in full force
                  and effect.

              

      

    

    
       

      IN WITNESS WHEREOF, the parties have caused this Fourth Amendment to be executed by their duly authorized representatives as of the Amendment Effective Date.

    

     

    	
            Accredo Health Group, Inc.

          	 	
            Aegerion Pharmaceuticals, Inc.

          

     

    	
            By:

          	
            /s/ Elizabeth Newport

          	 	
            By:

          	/s/ Joseph Shulman 

     

    	
            Name:

          	
            Elizabeth Newport

          	 	
            Name:

          	
            Joseph Shulman

          

     

    	
            Title:

          	
            VP

          	 	
            Title: 

          	
            Senior Vice President, Global Technical Operations

          

     

    	
            Date:

          	
            10/23/17

          	 	
            Date:

          	
            19 Oct 2017

          

    
       

       

      
        6

        
          
 

      

      Execution Version

       

      Attachment 1

       

      Business Partner Guiding Principles

       

    

    
      
        	 
	
                   Introduction

              
	 

      

       

      At Aegerion, we have an important mission – the development and commercialization of innovative therapeutics to treat debilitating and rare diseases. In working to achieve
        this goal, we set high standards for our own employees as well as for all who work on our behalf. Aegerion’s Business Partner Guiding Principles is based on our belief that working with business partners
        who follow ethical business practices is essential to our long-term success.

       

      
        	 
	
                   Expectations of Our Business Partners

              
	 

      

    

    
       

      
        	●	
                Conduct business in an ethical and transparent manner that is compliant with applicable laws, regulations and industry codes.

              

      

      
        	●	
                Develop and implement policies, systems and procedures that are consistent with these Business Partner Guiding Principles.

              

      

      
        	●	
                Provide routine compliance training to your employees relevant to their job function.

              

      

      
        	●	
                Maintain adequate compliance training records.

              

      

      
        	●	
                Designate a person who is responsible for compliance in your organization.

              

      

      
        	●	
                Establish a process for employees to report suspected wrongdoing and to publicize the process to your employees.

              

      

    

    
       

      
        	 
	
                   Ethical Approach to Business

              
	 

      

       

      At a minimum, each Business Partner must conduct business in accordance with the following:

    

    
       

      Anti-Bribery/Anti-Corruption

      
        
 

    

    
       

      
        	●	
                You must not offer or make any bribe or improper payment or improper transfers of value either directly or indirectly, whether in cash or in kind, to secure any kind of business advantage for Aegerion.

              

      

       

      
        	●	
                You must not encourage or allow others to offer or make improper payments.

              

      

    

    
       

      Privacy/Data Protection

      
        
 

    

    
       

      
        	●	
                Appropriately, and in compliance with all applicable laws and regulations, collect, use, and store personal information/data to ensure that privacy rights are protected for, among others, employees, healthcare professionals (HCPs) and
                  patients.

              

      

    

    
       

      
        7

        
          
 

      

    

    
      
        Execution Version

         

      

      Product and Product-Related Materials

      
        
 

    

    
       

      
        	●	
                Each Business Partner must comply with applicable laws and regulations related to the provision of information to HCPs, Government Officials (GOs), Government Entities (GEs), hospitals, payors and patients (if allowed and as required
                  under local law/codes) about Aegerion’s products and Aegerion’s disease states of interest. This includes knowing when Aegerion’s products can be promoted and what constitutes promotion.

              

      

       

      
        	●	
                Materials to be Used with HCPs, GOs, payors and patients (if permitted):

              

      

    

    
       

      
        		○	
                Materials must have been approved or provided by Aegerion.

              

      

       

      
        		○	
                Any materials used must be accurate and balanced; in addition, promotional materials must always be consistent with the local market authorization/label.

              

      

    

    
       

      Interactions with Healthcare Professionals and Government Officials

      
        
 

    

    
       

      Each Business Partner must be able to demonstrate that, in its interaction with third parties (including HCPs) on behalf of Aegerion, it has developed and implemented
        appropriate standards and policies to maintain compliance with applicable laws, regulations and industry codes.

       

      Interactions may include the engagement of HCPs or GOs in a professional capacity for their expertise in particular areas that are relevant to Aegerion products or
        research.

    

    
       

      
        	●	
                Prohibition of Inducements

              

      

    

    
       

      
        		○	
                Never offer, promise or provide inducements.

              

      

       

      
        		○	
                Inducements include payments or other items of value with the intent of, directly or indirectly, encouraging or influencing a decision, or influencing or encouraging the recipient to purchase, prescribe or recommend an Aegerion
                  product.

              

      

    

    
       

      
        	●	
                Legitimate Business Need and Written Agreement

              

      

    

    
       

      
        		○	
                Engage HCP/GOs to provide services only when there is a legitimate, documented business need and there is a written agreement in place.

              

      

    

    
       

      
        	●	
                HCP/GO Selection Criteria

              

      

    

    
       

      
        		○	
                Base the selection of HCP/GOs as service providers on their qualifications (e.g. skills and expertise) to perform the required task.

              

      

       

      
        		○	
                Engage only the minimum number of HCP/GOs necessary to satisfy the legitimate business need.

              

      

    

    
       

      
        	●	
                Fair Market Value

              

      

    

    
       

      
        		○	
                Ensure that payments are reasonable, based on prevailing rates of the HCP/GO’s home country, and only for bona fide services actually provided.

              

      

    

     

    
      8

      
        
 

    

    
      Execution Version

       

    

    
      	●	
              Disclosure of Payments and Transfers of Value

            

    

    
       

      
        		○	
                Payments and other transfers of value, including grants and donations, must be accurately recorded and reported to applicable governmental or industry agencies, as and when required by law or country code.

              

      

    

    
       

      
        	●	
                Educational Grants:

              

      

    

    
       

      
        		○	
                Do not give Educational Grants to individual HCPs.

              

      

       

      
        		○	
                Never give a grant to encourage or influence a decision, or influence or encourage the recipient to purchase or prescribe an Aegerion product.

              

      

       

      
        		○	
                Award grants only to entities that have a legitimate right to receive Educational Grants, as determined by local tax law.

              

      

       

      
        		○	
                Establish a Grant review process that is void of commercial influence.

              

      

    

    
       

      
        	●	
                Gifts, Hospitality and Travel

              

      

    

    
       

      
        		○	
                Ensure that hospitality and travel are only provided in conjunction with a legitimate business activity, and are not extravagant.

              

      

       

      
        		○	
                Select venues for business activities that are modest by local standards and conducive for business activities.

              

      

       

      
        		○	
                Follow local industry codes regarding gifts to HCP/GOs, but in all instances the gifts must be nominal in value and not for the personal benefit of the HCP/GO.

              

      

    

    
       

      
        	●	
                No Political Donations

              

      

    

    
       

      
        		○	
                Do not provide political donations to government officials in connection with any activities related to Aegerion.

              

      

    

    
       

      
        	●	
                Fair Competition

              

      

    

    
       

      
        		○	
                Business should be conducted consistent with fair and vigorous competition and in compliance with all applicable anti-trust laws.

              

      

    

    
       

      Interactions with Patient
          Organizations and Patients

    

    
      
        
 

       

      
        		●	
                Do not promote to Patient Organizations or patients.

              

      

       

      
        		●	
                You should always respect the independence of a Patient Organization; do not use the organization to promote or recommend Aegerion products.

              

      

    

    
       

      
        	 
	
                   Implementation

              
	 

      

       

      We expect our Business Partners to read and take reasonable steps to ensure its activities comply with the Aegerion Business Partner Guiding Principles and to take
        appropriate action in the event that a potential violation is discovered. These steps may include:

    

    
       

      
        9

        
          
 

      

      
        Execution Version

         

      

    

    
      
        		●	
                Developing, implementing and providing routine training on policies and procedures appropriate for the Business Partner’s business activities.

              

      

       

      
        		●	
                Communicating to your employees Aegerion’s expectations of compliance with these Business Partner Guiding Principles.

              

      

       

      
        		●	
                Developing and implementing appropriate business mechanisms to monitor for compliance with these Business Partner Guiding Principles.

              

      

    

    
       

      It is each Business Partner’s responsibility to obtain its own legal counsel and its own legal advice, as required.

    

    
       

      
        
 

       

      / have read, understand and agree to comply with Aegerion’s Business Partner Guiding Principles.

       

      Business Partner Legal Entity Name: Click here to enter text.

       

      Name of Authorized Representative: Click here to enter text.

       

      Signature:

       

      Date: Click here to enter text. 

    

    
      
        10

        
          
 

      

       

    

  

  Execution Version

   

  ATTACHMENT – PERSONAL DATA

   

  ADDITIONAL TERMS AND CONDITIONS FOR THE COLLECTION, USE, DISCLOSURE,

    RETENTION OR 

      PROCESSING OF PERSONAL DATA

   

  With regard to the Agreement, Service Provider may gain access to “Personal Data,” which shall mean any information which identifies or is capable of identifying a living individual, or
    as otherwise defined as Personal Data” by applicable laws, including, without limitation, (a) an individual’s name, address, phone number, e-mail address, Social Security number or other country identifier, driver’s license number, bank account
    information, or credit card information; and (b) all information, data and materials, including without limitation, demographic, medical and financial information, that relate to (i) the past, present, or future physical or mental health or condition
    of an individual; (ii) the provision of health care to an individual; or (iii) the past, present, or future payment for the provision of health care to an individual.

   

  Service Provider agrees that, in the event any of the Services that Service Provider provides to AEGERION related to Personal Data are subcontracted out to a third-party subcontractor,
    Service Provider shall execute a written agreement with said third-party subcontractor that requires it to comply with privacy, security, and breach reporting requirements that are substantially similar to those set forth in this Attachment and to
    comply with all applicable laws.

   

  Collection, use, disclosure, retention and other processing of Personal Data may be regulated by certain privacy, data security, and breach notification laws.

   

  When collecting, using, disclosing, retaining or otherwise processing Personal Data pursuant to the Agreement, Service Provider agrees to comply with all applicable privacy, data
    security, and breach notification laws, rules and regulations that are applicable to its collection, use, disclosure or processing of Personal Data pursuant to the Agreement. For purposes of this Attachment, applicable privacy, data security, and
    breach notification laws, rules, and regulations include, but are not limited to, any law related to the transmission, communication or storage of Personal Data via mail, telephone, computer, wireless technology, facsimile, or other such means.

   

  Service Provider acknowledges and agrees that, as required and as appropriate under applicable laws, Service Provider will furnish notices to and/or obtain the prior and freely given,
    specific and informed consents and/or authorizations of the individuals to whom the Personal Data relate to collect, use, disclose, retain or otherwise process such data in order to provide the Services.

   

  Without limiting the foregoing and in addition to any other obligations under the Agreement, Service Provider further agrees as follows:

   

  

  a.       Service Provider agrees to collect, use, disclose, retain and otherwise process Personal Data only as permissible under applicable laws;

   

  b.       Access to data: only authorized persons should have access to the Personal Data; Service Provider shall restrict such access in accordance with applicable laws and
    its privacy policies.

   

  Any and all consents or authorizations collected by Service Provider from individuals relating to collection, use, disclosure, retention and other processing of the individual’s
    Personal Data must be retained by Service Provider in compliance with applicable data retention policies. Service Provider agrees to establish commercially adequate controls to prevent unauthorized access, use or disclosure of Personal Data. Service
    Provider will implement safeguards that reasonably and appropriately protect the confidentiality, integrity, and security of Personal Data in accordance with applicable

  
    11

    
      
 

  

   

  Execution Version

   

  laws. Service Provider agrees AEGERION and/or its representatives may audit Service Provider’s business policies, processes, books, records, and practices relating to collection, use,
    disclosure, retention and other processing of Personal Data in accordance with “ATTACHMENT – AUDIT” to this Agreement.

   

  Duty of cooperation with law enforcement authorities: Parties agree to cooperate with law enforcement authorities, especially in case of requests for information or during inspections.

   

  Any collection, use, disclosure, retention and other handling of Personal Data other than as contemplated by this Attachment, permissible by law, and the Agreement will be deemed a
    material breach of the Agreement and subject to the applicable provisions of the Agreement related to a material breach; and

   

  Service Provider agrees to work in good faith to mutually amend this Attachment at any time as requested by AEGERION to the extent required in order to comply with any applicable law
    relating to privacy, data security, and breach notification in those respective jurisdictions where Service Provider provides services and/or collect, use, disclose or otherwise process Personal Data pursuant to the Agreement.

  
    12

    
      
 

  

  Execution Version

   

  EXHIBIT E

   

  Adverse Event Reporting, Product Complaint Reporting, and Medical Information Handling

   

  	I.	Adverse Event (AE) Reporting

   

  Service Provider (Accredo) shall report to Aegerion Pharmacovigilance (PV) vendor (United BioSource Corporation [UBC]) within one (1) business day after first becoming aware of any
    potential adverse event (AE). “Adverse Event” means any untoward event associated with the use of an Aegerion product, whether or not considered drug related, including events occurring in the normal course of use of a prescription drug; any drug
    overdose (whether accidental or intentional); any drug abuse, withdrawal, or lack of expected effect of the drug. AE also includes: drug exposure via a parent (during conception, pregnancy, breastfeeding, etc.), misuse, dependence, unintended
    beneficial effects, medication errors, off-label use* (all with or without an adverse drug experience), and suspected transmission of infectious agent via a medicinal product, occupational exposure, and drug-drug interactions.

   

  The following table lists examples of additional events that should be documented and transferred in addition to AE (this table is not an all-inclusive list):

   

  	Additional Events	Clarification

            and/or Example
	Abnormal test findings	 
	Drug Abuse	Persistent or sporadic, intentional excessive use of medicinal products which is accompanied by
          harmful physical or psychological effects.
	Lactation exposure (to infant)	Defined as the exposure of an infant/child to a medicinal product during breast-feeding/lactation.
	Hospitalization	 
	Lack of compliance	Any information suggesting the patient does not take the prescribed medication or follow a prescribed
          course of the treatment, such as failure of proper preparation, or using the correct dose, frequency, or route
	Lack of efficacy/effect	Any information that questions the efficacy or therapeutic effect of a product, for example the
          product isn’t working as indicated in the product labelling (i.e. for licensed indications only).
	Medication error	
          “medication error”- where the patient used the product

           

          “potential medication error”-patient noticed before the product was used

           

          A potential medication error is any unintentional error in the

        

   

  
    13

    
      
 

  

  Execution Version

   

  	 	prescribing, dispensing, or administration of a medicinal product while
          in the control of the healthcare professional, patient or consumer that was identified before the drug was administered to the patient or before the patient ingested any drug.
	Missed dose	E.g., patient forgot, supply ran out
	Misuse	Situations where the medicinal product is intentionally and inappropriately used not in accordance
          with the authorized product information.
	Off-label use*	Situations where a medicinal product is intentionally used for a medical purpose not in accordance
          with the authorized product information (including an indication, dose, administration method, patient group, storage condition or legal status of supply) not on the license or against a contraindication.
	Overdose	Occurs when a patient takes more than the prescribed amount. The product is ingested or administered
          in quantities and/or concentrations above the recommended/scheduled dosage large enough to overwhelm the homeostasis, disrupting wellbeing, causing severe illness and/or death.
	Occupational Exposure	Drug exposure as a result of one’s occupation, with or without associated symptoms/event.
	Pregnancy Exposure (to fetus)	Defined as an exposure of the male or female parent to a medicinal product at or around the time of
          conception (up to 3 months before conception) or at any time during pregnancy until birth and exposure of the fetus to a medicinal product (e.g., breastfeeding). Both intentional and unintentional exposures will be reported.
	
          Prescribed/Accidental overdose

        	more than on license/packaging
	Transmission, or suspected transmission, of an infectious agent	 
	Unexpected benefit	 
	Use of a product against a Contraindication 	 

   

  * The Juxtapid and Myalept REMS programs require the product to be dispensed only to patients who have a confirmed diagnosis of the indicated condition. “Off-label use” includes any
    reports of use for an ICD-10 code inconsistent with the approved indication for such product or reports that include information that is indicative with use for an indication other than the one that is approved. The

  
    14

    
      
 

  

  Execution Version

   

  Aegerion Compliance Department (novelioncompliance.tnwreports.com or 855-233-8089) must be notified within one (1) business day of receipt of all potential
    reports of off-label use.

   

  Accredo shall capture the following information for each AE and report it to UBC on the Accredo Adverse Event Form attached to the Agreement as Exhibit A: (a) date
    information/complaint received, (b) patient identifiers, (c) reporter name and contact information, (d) date AE occurred, (e) suspect product name, NDC (when available), lot number (when available), dose, date of administration (when available), and
    (f) description of the AE. Accredo shall maintain records of all AE reports on source documentation or entered into an Accredo system for at least three years and shall make all such records available to Aegerion upon request within two (2) business
    days’ notice. In the event of a regulatory inspection, Aegerion has the right to request copies of records to be delivered to it within one (1) business day.

   

  Accredo is responsible for:

  		●	Identifying and recording details of any AEs and forwarding it to UBC PV for processing. 

  

  Ensuring that if the AE also involves a Product Quality Complaint (PC), the PC will also be reported

  separately to Aegerion QA ([***]).

   

  Accredo is not responsible for:

  	 	●	Reporting an AE to the Regulatory Authorities.

  	 	●	Proactively obtaining follow-up information on an AE.

  	 	●	Reporting AEs from Aegerion sponsored clinical trials.

  	 	○	If any are inadvertently reported to Accredo, Accredo will obtain any details provided by the caller including the Clinical Trial number and forward back to UBC ([***]) to handle.

  	 	●	Reporting AEs from the published literature, for example, from clinical papers, journal letters, newspapers, social media, etc.

   

  	A.	Transmission and Reporting times of AE cases including any combination AE and Product Complaint (PC) cases to Aegerion Pharmacovigilance (PV)

  	 	i.	Transmission of Reports
	 	 	 

  	 	●	All AEs will be posted to the UBC Aegerion portal.

  	 	○	An Accredo representative will post the AE form to the UBC Aegerion portal within the Accredo library.

  	 	○	Accredo will set-up from the portal automatic alerts to get the confirmation that the AE reports has correctly been posted to this portal. In case no alert would be received, the Accredo representative will investigate and send the AE
          documentation by email to UBC ([***]).

  	 	○	UBC Safety Scientist or designee will acknowledge by email to [***] the receipt of the AE report.

   

  		●	Note: If a PC accompanies an AE, an AE and PC will each be reported. Refer to Product Complaint Reporting section A, ii.

  		●	In the event that the UBC Aegerion portal is down, reports would be transmitted via email or e-fax to [***].

  		●	In the event an AE or PC report is indicative a potential off label use of the product, Accredo will advise Aegerion Compliance of the report identifying number within one (1) business day.

   

  
    15

    
      
 

  

   

  Execution Version

   

  		ii.	Timelines

   

  	 	●	For Accredo, all AE reports will be transferred to the UBC Aegerion portal within one (1) business day Monday to Friday.

  	 	○	AEs received by Accredo during non-business hours or holidays will be processed within the next business day.

  	 	●	Acknowledgments of receipt will be received from the portal automatic alerts by the UBC representative following the receipt of the AE report.

   

  	 	iii.	Reconciliation

   

  	 	●	An Accredo representative will generate a weekly AE reconciliation report including a list of AE reports received for the week and post to the UBC Aegerion portal.

  	 	■	UBC Safety Scientist will set-up from the portal an automatic alert to get this list of AE reports from Accredo as soon as it is posted to the portal

  	 	●	UBC Safety Scientist or designee will acknowledge by email to [***] the receipt of the weekly reconciliation report. A confirmation that reconciliation has been performed by UBC will be sent to [***] including identified discrepancies if any
          within two (2) business days.

   

  		II.	Product Quality Complaint (“PC”)

   

  Product Complaint – Any communication, written or oral, that alleges deficiencies relative to the identity, quality, stability, reliability, effectiveness or performance of a product
    after it is released for distribution. A product complaint includes any communication which alleges deficiencies relative to the packaging, labeling, immediate container, closure or contents of the drug, and/or any allegation of poor pharmaceutical
    quality such as chipped, split or otherwise faulty drug product capsule or drug product vial, aesthetic defects (off-color, off-shape, inconsistent surface texture, and off-flavor), or report of drug sub-potency or super-potency. “Sub-potency” only
    includes drug product lack of effect (including decreased, incomplete or delayed drug effect) reported at the established therapeutic dose.

   

  Accredo shall also report to Aegerion Quality Assurance (QA) ([***]) within one (1) business day after first becoming aware of any PC.

   

  	A.	PROCEDURE FOR INITIAL INTAKE OF PRODUCT COMPLAINT 

  		i.	PC Reporting Responsibilities

   

  		●	Accredo is responsible for initial documentation of PCs and forwarding this information to Aegerion QA through the email address [***] for further follow up and evaluation.

  		●	Accredo ensures that if a PC also involves an AE or special situation, this is also reported separately to Aegerion PV (see Section I.A.) and Aegerion QA is copied simultaneously on the Accredo AE form.

   

  	 	ii.	PC Reporting Information to Obtain

   

  As per the table below, the following information will be attempted to be obtained for the PC report.

   

  	Reporting Information to Obtain
	Reporter	●                Reporter name

   

  
    16

    
      
 

  

  Execution Version

   

  	 	●                Telephone number
	Product	●                Product

          name
	 	●                NDC
	●                Lot

          number
	●                Expiration

          date
	●                Strength
	●                Pack

          size
	●                Quantity

          of product affected
	●                Available

          for return to Aegerion?
	●                Has the product been used in a patient?
	Complaint	A detailed description of the PC

   

  	iii.	Transmission and Reporting Times of PC cases to Aegerion

   

  		●	All PCs are e-mailed to Aegerion QA ([***]) within one (1) business day.

  		●	Accredo receives acknowledgement of receipt of case by Aegerion QA within 24 hours of receipt.

   

  	iv.	Restitution

   

  	 	●	Restitution of PCs will be handled by Aegerion QA.

   

  	v.	Reconciliation

   

  		●	Accredo sends a weekly reconciliation report to [***] which includes a list of the previous weeks PCs with the information set forth in the table below.

  		●	Aegerion will acknowledge by email to Accredo ([***]) the receipt of the weekly reconciliation report.

  		●	A confirmation that reconciliation has been performed by Aegerion QA is sent to Accredo including identified discrepancies if any, within two (2) business days.

  		●	Any discrepancies noted by Aegerion QA is followed up with Accredo within one (1) business day and any missed PC report is sent immediately to Aegerion.

   

  	Field #	Data Element	Max Length	Required 

            (Yes, No, If Available)	Notes
	1	Drug Name	10	Yes	 
	2	PC Date Reported to MFR	10	Yes	Date Format: MMDDYYYY
	3	Unencrypted Patient ID	15	Yes	Not Encrypted
	4	Patient Date of Birth	8	Yes	Not Encrypted

   

  	III.	Training

   

  Accredo shall ensure that its employees, subcontractors and agents who perform services under this Agreement or any associated Statement of Work, are trained in AE reporting and PC
    reporting before

  
    17

    
      
 

  

  Execution Version

   

  such employees, subcontractors or agents commence services. Accredo shall ensure that all such employees, subcontractors and agents are re-trained on an annual basis and shall maintain
    contemporaneous records of such training for all persons providing services hereunder or under an associated Statement of Work and shall send records to Aegerion at the time of completion and within two business days’ notice when requested (or sooner
    if requested for an inspection or audit). Aegerion point of contact for Accredo shall provide training materials, as needed.

   

  Per the modification to the Juxtapid REMS Program approved by FDA on January 3, 2017, and subsequent revisions thereto, Accredo will designate an Authorized
    Representative for each pharmacy who must complete the Juxtapid online Training Module and complete the Pharmacist Enrollment Form (RXEF). The Training Certificate and the RXEF must be submitted to the Juxtapid REMS Coordinating Center by fax [***] or
    email [***] prior to the pharmacy certification and the dispensing of Juxtapid by the pharmacy. Pharmacy certification will be confirmed in writing by the Juxtapid REMS Program.

   

  The Authorized Pharmacist for each Juxtapid dispensing pharmacy is responsible for ensuring training to the requirements of the REMS Supplement are completed by
    relevant pharmacy staff. The on-line module should be used for training of all of the pharmacy staff.

   

  Accredo is required to verify every 12 months that the authorized representative’s name and contact information corresponds to that of the current designated
    authorized representative for DLSS, if different the pharmacy must be required to re-certify with a new authorized representative in a timely manner, and in no event later than thirty (30) calendar days after Accredo’s first knowledge thereof. The
    dispensing of Juxtapid by a pharmacy that is not certified in the Juxtapid REMS Program will be classified as a violation of the Juxtapid REMS Program requirements and may trigger corrective action or additional actions by Aegerion.

   

  	IV.	Medical Information for Health Care Providers (HCPs) or Consumers not enrolled in the Accredo Patient Support Services Programs

   

  	 	A.	Function

  Medical Information is responsible to provide responses to unsolicited medical inquiries involving Aegerion products. Medical inquiries from HCPs that are not related to
    reimbursement or prior authorization needs should be transferred to the Medical Information Call Center (MICC). In addition, consumers who do not wish to enroll in the Product Patient Support Services program and have questions concerning Aegerion
    products can also be transferred to the MICC.

   

  	 	B.	Medical Information Contact Information

  	 	i.	Medical Information: [***] Monday through Friday 8 am to 5:30 pm EST or [***].  
	 	ii. 	Live caller: 

  	 	1.	During normal business hours: Provide phone number [***] and warm transfer caller. Provide contact details obtained to the MICC agent when call is connected.

  	 	2.	After hours: provide phone number [***] and inform of business hours.

  	 	a.	An after-hours call service is available for urgent inquiries only.

  	 	iii.	Written request: Any requests for information received via email or in writing shall be transferred to [***].

   

  
    18

    
      
 

  

   

  Execution Version

   

  	 	iv.	Any exchange of adverse event (AE) or product complaint (PC) details prior to the transfer of the live call or written request shall be handled according to AE and PC reporting procedures.

  	 	1.	Note in the AE or PC report that the case has been transferred to MICC to indicate a potential duplicate case.

   

  19Exhibit 10.13

   

  AMRYT PHARMA
        PLC

   

  EMPLOYEE SHARE
        OPTION PLAN 2019

  Adopted on 25 September 2019

   

  
  
     

  

  
     

  

  
   

  AMRYT PHARMA PLC

  EMPLOYEE SHARE OPTION PLAN 2019

   

  Rules 

   

  Definitions

   

  		1.	The Plan is established by an ordinary resolution of the Shareholders passed on September 25th
          2019. The purpose of the Plan is to provide for the granting of share options to Directors and Employees of and Consultants to
          the Company and its subsidiary and associated companies in accordance with the provisions hereinafter contained.

   

  		2.	In the Plan the following expressions bear the following meanings:-

   

  	(a)	"Associated Company"	means a company under the Control of the Company or any Subsidiary of the Company or any combination thereof or in which the Company and/or its Subsidiaries have a shareholding interest of 20% or greater;
	 	 	 
	(b)	"the Board"	means the Board of Directors for the time being of the Company or a duly constituted committee of the board of directors;
	 	 	 
	(c)	"the Company"	means Amryt Pharma Plc, a company registered in England and Wales under number 12107859
	 	 	 
	(d)	"Consultant"	means any individual or company who has a consultancy agreement with the Company or a Participating Company;
	 	 	 
	(e)	"Control"	has the same meaning as in Section 840 of Income and Corporation Taxes Act 1988;
	 	 	 
	(f)	“Date of Grant”	means the date on which an Option is granted as determined by the Board and specified in the Option Certificate;
	 	 	 
	(g)	"Directors"	means in relation to the Company or a Participating Company its board of directors and “Director” shall be construed accordingly and shall include non-executive members of any such board of directors;
	 	 	 
	(h)	"Employee"	means an employee of the Company or a Participating Company (other than one who is a Director of the Company or of a Participating Company);  
	 	 	 
	(i)	"Final Option Date"	means in relation to an Option the last date upon which any part thereof may be exercised under Clause 7, which date shall be determined by the Board and specified in the Option Certificate, but in no event shall be
          later than the date preceding the tenth anniversary of the Date of Grant;

   

  
  
    	 	2	 

  

  
     

  

  
   

  	(j)	“Market Value"	means the price which in the opinion of the Board represents the fair market value of a Share, having regard in circumstances where the Shares are traded on the Markets, to the prices prevailing in the
          Markets;
	 	 	 
	(k)	“Markets”	the AIM market operated by the London Stock Exchange plc and any recognised investment exchange (as defined by section 285 of the Financial Services and Markets Act 2000) the company is or will be listed on including
          for these purposes the National Association of Security Dealers Automated Quotation Market;
	 	 	 
	(l)	"Nominated Person"	means a person who shall have been nominated for the purpose of the Plan pursuant to Clause 3(a);
	 	 	 
	(m)	Notice of Exercise”	means a notice of exercise of an Option in the form set out in Schedule 2 to the Plan or such other form approved by the Board;
	 	 	 
	(n)	"Option"	means an option granted pursuant to the Plan;
	 	 	 
	(o)	"Option Certificate"	means a certificate executed under the seal of the Company evidencing the grant of an Option, in the form set out in Schedule 1 to the Plan or such other form approved by the Board;
	 	 	 
	(p)	"Option Price"	means the price at which a Share must be subscribed on exercise of an Option;
	 	 	 
	(q)	"Participant"	means any Nominated Person (or, in the event of his death, his personal representative) who is for the time being the holder of an Option;
	 	 	 
	(r)	"Participating Company"	means any company being the Company or an Associated Company to whom the Board has extended the Plan;
	 	 	 
	(s)	"the Plan"	means the Amryt Pharma Plc Employee Share Option Plan 2019, consisting of these rules, as amended from time to time in accordance with the provisions in that regard herein contained;
	 	 	 
	(t)	“Remuneration Committee”	means the committee of non-executive directors of the Board responsible for assessing and making recommendations concerning the remuneration of executive directors and senior employees of the Company and its
          Associated Companies;
	 	 	 
	(u)	"Shares"	means the Ordinary Shares of £0.06 each in the capital for the time being of the Company; and
	 	 	 
	(v)	“Subsidiary”	has the meaning assigned in Section 1159 of the Companies Act 2006;

   

  
  
    	 	3	 

  

  
     

  

  
   

  	(w)	“Tax Liability”	the total of all and any tax, including income and employee NIC, (or their equivalents in any jurisdiction) for which any Participating Company is or may be liable to account.

   

  The Rule headings are for ease of reference
    only and shall not in any way affect the interpretation hereof.

   

  Eligibility
        for Participation

   

  	3.	(a)	Power of Board

   

  The Plan is available
    for Directors, Employees or Consultants who shall be nominated for the purpose by the Board.

   

  		(b)	Absolute Discretion

   

  The Board shall
    at its absolute discretion determine whether or not a person is a Director, Employee or Consultant.

   

  		(c)	No Right

   

  No person shall
    be entitled as of right to participate in the Plan and the decision as to who shall have the opportunity of participating and the
    extent of his participation will, subject to the Plan, be made by the Board at its absolute discretion.

   

  LIMITS

   

  	4.	(a)	Ten Year Limit

   

  No Option shall be granted under the
    Plan on a date later than ten years after the date of adoption of the Plan by the members of the Company.

   

  		(b)	Overall Limits for Plan at Adoption Date

   

  Subject to Rules 13 and 14, the maximum
    number of Shares over which Options may be in issue at any one time under the Plan shall be 10% of the issued share capital in
    the Company.

   

  	5.	(a)	Power to Grant

   

  Subject to the provisions
    of Rule 21(a), the Board may on behalf of the Company grant Options to Nominated Persons at any time or times within ten years
    of the date of adoption of this Plan by the members of the Company.

   

  		(b)	Non-Assignable

   

  Options shall be
    personal to the grantee and non-assignable, subject to Rule 8, unless the Board in its sole discretion consents to an assignment
    or transfer. Any purported transfer, assignment, mortgage or charge of an Option, without the consent in writing of the Board,
    shall cause the Option to lapse forthwith.

   

  
  
    	 	4	 

  

  
     

  

  
   

  		(c)	Certificates

   

  An Option Certificate
    shall be issued to a Participant in respect of each Option.

   

  		(d)	Right to Renounce

   

  An individual to
    whom an Option has been granted may, by notice in writing within 30 days after receipt of the Option Certificate, renounce such
    Option, in which event it shall be deemed never to have been granted.

   

  OPTION PRICE

   

  		6.	The Option Price in relation to an Option shall be determined by the Board but shall not be less
          than the nominal value of a Share. If the option is to be granted at Market Value the Market Value per Share of the Shares comprised
          in the Option is to be computed as at the day prior to the Date of Grant.

   

  PERIODS
      FOR EXERCISE OF OPTIONS

   

  	7.	(a)	Subject to Rules 7(b), 8, 9, 10 and 16, an Option may be exercised at any time or times prior to the Final Option Date. An Option shall expire immediately after the Final Option Date to the extent that it has not
          been exercised.

   

  		(b)	The Board may when it grants an Option at its entire discretion attach a condition thereto such
          that the Option or portion(s) thereof may not be exercised until a period(s) (not exceeding four years) has elapsed from the Date
          of Grant. Such vesting condition(s) will be set out in the Option Certificate.

   

  		(c)	The Board may when it grants an Option at its entire discretion attach a condition relating to
          future performance by the Director, Employee or Consultant such that the Option or portion(s) thereof may not be exercised until
          such conditions have been met. Such conditions will be set out in the Option certificate.

   

  DEATH AND
      TRANSFER OF RIGHTS

   

  	8.	(a)	In the event of the death of a Participant before the Final Option Date the personal representative of such deceased Participant may, at any time and from time to time but no later than one year after the date of
          such death (or, if earlier, the Final Option Date), exercise the Option, to the extent exercisable on the date of the Participant’s death, in whole or in part.  Upon the expiration of such period the Option shall lapse to the extent that it shall
          not have been so exercised.  

   

  		(b)	To the extent an Option is not exercisable on the date of a Participant’s death, the Option
          shall lapse on such date unless the Board in its sole discretion determines that such Option shall be exercisable in whole or in
          part after such date and if the Board does so determine, the Option shall be exercisable in accordance with Rule 8(a).

   

  
  
    	 	5	 

  

  
     

  

  
   

  RETIREMENT, RESIGNATION ETC.

   

  	9.	(a)	If a Participant ceases to be an Employee or Director or Consultant on account of:-

   

  		(i)	retirement at normal retirement age; or

  		(ii)	resignation or early retirement due to disability or ill-health (such matter to be determined by
          the Board in its absolute discretion);

   

  the Participant
    may at any time and from time to time but no later than one year after he shall have so resigned or retired (or, if earlier, the
    Final Option Date), exercise the Option, to the extent exercisable on the date of such resignation or retirement, in whole or in
    part. Upon the expiration of such period the Option shall lapse to the extent that it shall not have been so exercised.

   

  		(b)	To the extent an Option is not exercisable as of the date
          of a Participant’s resignation or retirement as described in Rule 9(a), the Option shall lapse on such date unless the Board
          in its sole discretion determines that such Option shall be exercisable in whole or in part after such date and if the Board does
          so determine, the Option shall be exercisable in accordance with Rule 9(a).

   

  		(c)	If a Participant ceases on account of resignation, retirement, dismissal (subject to the provisions
          of Rule 9(d) or otherwise (except on death, retirement or resignation or early retirement due to disability or ill-health) to be
          an Employee or Director or Consultant, each Option held by the Participant, to the extent not exercisable at the date of such cessation,
          shall lapse on such date. To the extent an Option is exercisable at the date of such cessation, it may be exercised by the Participant
          in whole or in part within 90 days after such date (or, if earlier, until the Final Option Date), failing which it will lapse.
          Cessation shall be on completion of the appropriate notice period required from either the employee or Participating Company employing
          or engaging him to terminate the employment.

   

  		(d)	If a Participant’s employment or office or consultancy is terminated summarily for serious
          misconduct by the Participating Company employing or engaging him, each Option held by the Participant shall lapse in full immediately
          upon such termination.

   

  		(e)	Notwithstanding the foregoing provisions, the Board in its sole discretion may determine that if
          circumstances so warrant, an Option may be exercised after the Participant ceases to be an Employee, Director or Consultant during
          a longer period than the period provided under the foregoing provisions and/or that an Option, to the extent not exercisable on
          the date a Participant ceases to be an Employee, Director of Consultant, shall be exercisable in full or in part after such cessation
          and may be exercised within a period specified by the Board, but in no event may an Option be exercised later than the Final Option
          Date and an Option will lapse to the extent not exercised within the period specified by the Board.

   

  		(f)	In no circumstances shall any Participant who ceases to serve as an Employee or Director or Consultant
          be entitled to any compensation for any loss of any right or

   

  
  
    	 	6	 

  

  
     

  

  
   

  benefit or prospective right or
    benefit under the Plan which he might otherwise have enjoyed whether such compensation is claimed by way of damages for wrongful
    dismissal or other breach of contract or by way of compensation for loss of office or otherwise howsoever.

   

  MERGER OR TAKEOVER

   

  		10.	In the event that the Company is a party to a merger, takeover or other reorganisation, including
          but not limited to a court sanctioned compromise or scheme arrangement, pursuant to which a party or parties acting in concert
          obtain(s) Control of the Company, or the Board considers that this is about to occur, or notice is given of a resolution for the
          voluntary winding-up of the Company, each Option shall automatically accelerate and become exercisable in full as of a date specified
          by the Board, conditional upon such merger, takeover or other reorganisation or winding-up, and the Board shall, at its discretion,
          with respect to each Option:

   

  		(i)	request the Participant to exercise the Option within such period and subject to such conditions
          as the Board may at its discretion determine and if the Participant does not comply with such request the Option shall lapse on
          a date specified by the Board; or

   

  		(ii)	arrange for payment of a cash settlement to the Participant, in cancellation of the Option, equal
          per Share subject to the cancelled Option to the excess of the amount to be paid for a Share in the merger or takeover or reorganisation
          or winding up over the Option Price.

   

  The Remuneration
    Committee may make such other comparable arrangements to replace any Options (whether exercisable or not) as it determines in its
    discretion.

   

  For the avoidance of doubt, a reverse
    takeover by Amryt of another company will not result in an acceleration of share option vesting.

   

  PROCEDURES
      ON EXERCISE OF OPTIONS

   

  		11.	Upon the exercise of an Option in whole or in part the Participant shall deliver a Notice of Exercise
          and pay the Option Price in respect of the Shares for which the Option is being exercised to the Company, in cash or by cheque
          or by same-day sale exercise through a broker designated by the Company, or by any other means or arrangements reasonably approved
          by the Board, and shall deliver the Option Certificate to the Company and the Company shall issue the appropriate Shares to the
          Participant and deliver to the Participant any appropriate balance Option Certificate.

   

  		12.	All Shares issued on any exercise of an Option shall rank pari passu in all respects with the Shares
          already in issue.

   

  
  
    	 	7	 

  

  
     

  

  
   

  TAX LIABILITIES

   

  		13.	Each participant is responsible for all Tax Liability and will pay or enter into arrangements with
          the relevant Participating Company to pay all and any Tax Liability, failing which the Company shall not issue or transfer shares
          to the Participant on exercise of his Options.

   

  		14.	If requested by the Participating Company, the Participant shall enter into a joint election under
          section 431(1) or 431(2) of the Income Tax (Earnings and Pensions) Act 2003 or other relevant legislation in respect of shares
          to be acquired on exercise of an Option.

   

  BONUS, RIGHTS
      ISSUES, VARIATION IN SHARE CAPITAL

   

  		15.	If a consolidation or subdivision of a reduction of the share capital of the Company or if any
          other variation in the share capital of the Company occurs, the Board may make such adjustment to the Option Price and/or the number
          and/or class of Shares subject each Option and to the share limit set out in Rule 4(b) as it deems appropriate.

   

  		16.	If holders of Shares are granted rights to subscribe for further shares (such rights being related
          to the number of Shares held by them respectively) the Board shall at its absolute discretion decide whether the granting of such
          rights and the subscriptions made thereunder shall result in the depletion in the value of each Share and the Board may make such
          adjustment(s) to the Option Price and/or the number and/or class of Shares subject each Option and to the share limit set out in
          Rule 4(b) as it deems appropriate.

   

  NO SHARE
      ISSUES AT A DISCOUNT

   

  		17.	Notwithstanding anything herein contained no Option shall be granted to subscribe for any Shares
          at a discount to the nominal value of the Shares.

   

  LIQUIDATION

   

  		18.	In the event of a liquidator being appointed to the Company all Options shall ipso facto cease
          to be exercisable and (save to the extent, if at all, that the Board may prior to such liquidation at its absolute discretion determine)
          Participants shall not be entitled to damages or other compensation of any kind.

   

  EXCHANGE
      QUOTATIONS

   

  		19.	The Company will within five working days after the exercise of an Option apply for permission
          to deal in the Shares or securities of the Company (whichever one traded) issued pursuant to the exercise of Options on AIM or
          such other stock exchange upon which the Shares or securities are for the time being quoted.

   

  
  
    	 	8	 

  

  
     

  

  
   

  ALTERATIONS

   

  		20.	The Company may at any time by resolution of the Board vary, amend or revoke any of the provisions
          of the Plan in such manner as it considers fit.

   

  OBLIGATION
      TO KEEP UNISSUED CAPITAL

   

  		21.	The Company shall take all necessary steps (including the passing of resolutions of the Company)
          to ensure that the directors of the Company shall, at all times, be generally and unconditionally authorised to allot Shares pursuant
          to Options to Nominated Persons.

   

  TERMINATION

   

  	22.	(a)	The Plan may be terminated at any time by resolution of the Board.

   

  		(b)	Subsequent to any termination of the Plan under paragraph (a) of this Rule 20 the Company shall
          not grant any further Options but no such termination shall affect or modify any subsisting rights or obligations of Participants
          in respect of any Options and notwithstanding such termination the Company shall continue to administer and manage the Plan in
          accordance with the rules of the Share Option Plan.

   

  GENERAL

   

  	23	(a)	If the Shares are listed on a stock exchange or securities market, the Company and each Participant shall be subject to such insider dealing policy as the Company may implement from time to time for its officers and
          employees imposing restrictions on transactions in the Shares during specified periods.

   

  		(b)	In the event of any dispute or disagreement as to the interpretation of the Plan, or as to any
          question or right arising from or related to the Plan, the decision of the Board shall be final and binding upon all persons.

   

  		(c)	Any notice or other communication under or in connection with an Option and/or the Plan may be
          given by personal delivery or by sending the same by prepaid post

   

  		(i)	In the case of the Company to The Share Option Plan Administrator/ Company Secretary of the Company
          at its registered office;

   

  		(ii)	In the case of a Nominated Person or Participant, to his last known address provided to the Company,
          or to the address of the place of business at which he performs the whole or substantially the whole of his duties of his employment
          or engagement; and

   

  		(iii)	Where a notice or other communication is personally delivered, it shall be deemed to have been
          received at the time of delivery and where it is posted to an address within Ireland, it shall be deemed to have been received
          forty-eight (48) hours after it was put into the post properly addressed and stamped and where it is posted to an address outside
          Ireland, it shall be deemed to have been received on the fifth business day after

   

  
  
    	 	9	 

  

  
     

  

  
   

  the date it was put into the post
    properly addressed and stamped. If a Participant is an employee and is not on extended leave from employment, notice to such Participant
    may be sent by email to the address at the Company or the Participating Company at which the Participant customarily receives email
    correspondence in connection with his employment and shall be deemed to have been received upon transmission.

   

  		(d)	The Board shall be entitled to authorise any person to execute on behalf of a Participant, at the
          request of the Participant, any document relating to the Plan, insofar as such document is required to be executed pursuant thereto.

   

  		(e)	By participating in the Plan, each Participant consents to the holding and processing of personal
          data relating to him by the Company or any Participating Company for all purposes relating to the operation of the Plan which purpose
          include, but are not limited to:

   

  		(i)	administering and maintaining Participant records;

   

  		(ii)	providing information to tax and regulatory authorities;

   

  		(iii)	providing information to registrars, brokers and other third party administrators of the Plan;
          and

   

  		(iv)	providing information, on a confidential basis, to potential purchasers of the Company or the business
          in which the Participant is employed.

   

  		(f)	The Plan shall be governed by and construed and interpreted in accordance with English law and
          the Company and Participants agree to submit to the non-exclusive jurisdiction of the Courts of England in relation to any claim,
          dispute or difference which may arise hereunder.

   

  
  
    	 	10	 

  

  
     

  

  
   

  SCHEDULE 1

   

  OPTION CERTIFICATE

   

  AMRYT PHARMA PLC EMPLOYEE SHARE OPTION PLAN
      2019

   

  THIS DOCUMENT IS IMPORTANT

   

  	Name of Participant:	 	 
	 	 	 
	Address of Participant:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Date of Grant:	 	 
	 	 	 
	Number of Shares:	 	 
	 	 	 
	Option Price per Share:	 	 
	 	 	 
	Vesting Conditions:	 	 
	 	 	 
	Last Date on which Notice of Exercise of Option can be given (Final Option Date):	 	 

   

  THIS IS TO CERTIFY that the Participant
    named above was on the above Date of Grant granted an option to subscribe for the above number of Ordinary Shares (“Shares”)
    in Amryt Pharma plc (the “Company”) at the above Option Price per Share. This Option may not be transferred, assigned,
    mortgaged or charged by the Participant and any purported transfer, assignment, mortgage or charge will cause this Option to lapse
    forthwith. This Option is exercisable subject to and in accordance with the terms and conditions of the Amryt Pharma plc Plan 2019,
    a copy of which accompanies this Option Certificate.

   

  If the Participant wishes to renounce this
    Option, he may do so by notifying the Company in writing by 30 days after date of delivery of Option Certificate.

   

  Please note that each employee is entirely
    responsible for the declaration and payment of tax on any profits which may arise from the exercise of share options. The company
    accepts no liability whatsoever in relation to the payment of tax in this regard.

   

  
  
    	 	11	 

  

  
     

  

  
   

  	
          PRESENT when the common seal

          of AMRYT PHARMA PLC was affixed hereto:

        	 	 
	 	 	Signature
	 	 	 
	 	 	 
	 	 	Print name
	 	 	 
	 	 	 
	 	 	Signature
	 	 	 
	 	 	 
	 	 	Print name

   

  
  
    	 	12	 

  

  
     

  

  
   

  SCHEDULE 2

   

  NOTICE OF EXERCISE

   

  	TO:	The Secretary
	 	Amryt Pharma plc
	 	90 Harcourt Street
	 	Dublin 2

   

  Amryt Pharma plc ("The Company")

   

  Amryt Pharma plc Employee Share Option
        Plan 2019

   

  Date of Grant of Option:

   

  Option Price per Share:

   

  Total number of Shares subject to Option:

   

  I hereby exercise the above option in respect
    of ______________** Ordinary Shares in the Company.

   

  I enclose payment of the Option Price by [cheque][cash][cashless
    exercise][other method of payment].

   

  	Full Name:	 	 
	 	 	 
	Address:	 	 
	 	 	 
	Signature:	 	 
	 	 	 
	Date:	 	 

   

  **Note

   

  Insert the number of Shares in respect of which
    the option is exercised.

   

  
  
    	 	13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]